Member Info for Gizzard

FC they won't listen to you it was the same with ncyt, their loss our gain...

Starting its fresh move forward now, so much happening here the ELISA test is going into manufacture imminently and when news breaks this will really start to motor, gla who had the courage to invest when others didn't. NCYT Mk2 in the making...

Seen it all before with ncyt, gdr and avct, keep buying...

It just keeps coming back on any dip that's all you need to know - strength.

Who cares it's up 50% the next news will send up another 50% imo, don't lose out guys ncyt number two.

MMs can't cope with the demand, going ballistic now, this is Boris's baby he visited the factory 3/4 weeks ago an gave the green light.

10k block buyer here now, bring the test manufacturing news and see ya over a quid..

52p paid...

50p for starters no problem and with the ELISA test manufacturing starting very soon a £1 easily...

Following the same trajectory as ncyt another important step to manufacturing the first test next week.

Even after having the virus there’s no guarantee of immunity...

There is going to be no credible vaccine for at least 6 months this pandemic is just starting not slowing. Obviously the government want to start unwinding the lockdown but this virus is nasty. Think everyone’s getting a little complacent even the gov.
Gla we’ll need it.

So CB, LR, MC and IIs are going to sell up at this price - laughable, tell you what sell your shares if you’ve got any and be fooked...

Working with more partners to be announced with more rapid poc (point of care) tests for commercial and domestic use. This could really take off next week imo

d I r e c t o r s t a l k

LSE block it

************* is the missing bit

https://www.*************.net/avacta-group-ceo-alastair-smith-looking-to-develop-further-covid19-testing-kit-partnerships-interview/

They’re just attention seekers, quite sad really some of them can’t spell.

There's a chunky trade just in 213K Pounds it took it in it's stride buy or sell it matters not.